Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)

Ann Med. 2010 Apr;42(3):231-40. doi: 10.3109/07853891003652534.


Background: The lowering of cholesterol concentrations in individuals at high risk for cardiovascular disease improves clinical outcome. Xuezhikang has a marked impact on lipids.

Methods: In this randomized, double-blinded, placebo-controlled, parallel-group clinical trial, a total of 2704 hypertensive patients with previous myocardial infarction (MI) were assigned either to placebo (n = 1341) or to Xuezhikang (0.6 g twice daily, n = 1363) for an average of 4.5 years. The primary end-point was recurrent coronary events; the secondary end-point was all-cause mortality and other clinical events, including adverse effects.

Results: There were no differences between the Xuezhikang and placebo group in base-line characteristics. However, Xuezhikang treatment reduced the incidence of coronary events by 43.0% (P = 0.02), deaths from coronary heart disease (CHD) by 30.0% (P < 0.01), and all-cause mortality by 35.8% (P = 0.001).

Conclusions: This study, for the first time, demonstrated that long-term Xuezhikang therapy resulted in significant reduction in cardiovascular events and death in Chinese hypertensive patients with previous MI in a safe manner.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • China / epidemiology
  • Coronary Artery Disease / etiology
  • Coronary Artery Disease / prevention & control*
  • Double-Blind Method
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Humans
  • Hypertension / complications
  • Hypertension / diet therapy*
  • Hypertension / mortality
  • Incidence
  • Kaplan-Meier Estimate
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Myocardial Infarction / complications*
  • Young Adult


  • Drugs, Chinese Herbal
  • Lipoproteins
  • xuezhikang